Novel therapeutic approaches targeting genetic mutations in BRAF, MEK, RAS family of proteins, c-KIT, c-Met, VEGFR, and PI3K have been illustrated and implicated in the reduction of cell proliferation and cell survival in melanoma as well other forms of cancer. This evidence concerns the gene MAP2K7 and melanoma.